Marrone Bio Innovations to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th
Marrone Bio Innovations (NASDAQ: MBII) will present at the Canaccord Genuity 40th Annual Growth Conference from August 11 to 13, 2020. CFO Jim Boyd is set to lead a presentation on August 12 at 4:30 PM Eastern Time, followed by one-on-one meetings with CEO Kevin Helash. The company focuses on sustainable agricultural solutions, boasting over 400 patents and an innovative product line aimed at enhancing crop protection and health. More details can be found on their website.
- None.
- None.
DAVIS, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today that management will present at the Canaccord Genuity 40th Annual Growth Conference. The event is being held virtually and will take place August 11 to 13, 2020.
Jim Boyd, Chief Financial Officer, is scheduled to host a virtual presentation during the conference and will also participate in virtual one-on-one meetings throughout the day with Chief Executive Officer Kevin Helash.
Canaccord Genuity 40th Annual Growth Conference
Date: Wednesday, August 12, 2020
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific Time)
Webcast Link: http://wsw.com/webcast/canaccord42/mbii/
For more information on the Canaccord Genuity 40th Annual Growth Conference or to schedule a one-on-one meeting, please contact your Canaccord Genuity representative.
About Marrone Bio Innovations
Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Zelto® Jet Oxide® and Jet Ag® and Zequanox®, with a breakthrough bioherbicide and biofumigant in the Company’s product pipeline. MBI’s Pro Farm Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP-110®, LumiBio™, LumiBio Valta™, LumiBio Kelta™, Foramin®.
Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the timing of Helash’s employment and appointment to the company’s board of directors and the company’s goals for future performance. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the Company’s products, weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.
Investor Relations Contact:
Luke Zimmerman
Senior Vice President
MZ Group – MZ North America
949-259-4987
MBII@mzgroup.us
www.mzgroup.us
FAQ
When will Marrone Bio Innovations present at the Canaccord Genuity Growth Conference?
Who is presenting for Marrone Bio Innovations at the Canaccord Genuity Conference?
What is the primary focus of Marrone Bio Innovations?
How many patents does Marrone Bio Innovations hold?
Where can I watch Marrone Bio Innovations' presentation?
